Vedistry, a division of Charak Pharma, has announced the release of Fortyfitt Woman Tablets, a nutritional supplement that assists women in their forties with a smooth transition from perimenopause to menopause and overall health.
Pfizer will acquire Global Blood Therapeutics, a biopharmaceutical company committed to the discovery, development, and delivery of life changing treatments that bring support to underserved patient communities, starting with sickle cell disease.
Alembic Pharmaceuticals announced that its wholly-owned subsidiary Aleor Dermaceuticals has received final approval from the US Food and Drug Administration for its generic version of a topical gel used to treat acne vulgaris.
A 23-month-old baby with Spinal Muscular Atrophy-1 (SMA-1), a rare genetic disorder, was given Zolgensma Gene Therapy, the only treatment available, in the form of a Rs 16 crore injection supplied by Novartis.
Nubeqa has been approved by the FDA to treat adults with metastatic hormone-sensitive prostate cancer. The green light allows Nubeqa to be used in advanced-stage prostate cancer as well as non-metastatic castration-resistant prostate cancer.
Cell therapy company Eyestem, based in Bengaluru, has raised $6.4 million in Series A round led by three major pharmaceutical companies: Biological E Limited (BE), Alkem, NATCO, and Anurag and Karan Bagaria, Kemwell Biopharma’s promoters.
The label expansion for Myfembree’s use in
endometriosis has been won by Myovant
and Pfizer. Myfembree received its first FDA
approval in May to treat heavy menstrual
bleeding associated with uterine fibroids in
premenopausal women.